| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 22 Sep 2026 |
Form 4: Coll Crespo Blas, CHIEF MEDICAL OFFICER
Gave up 10,626 shares to cover exercise price or tax ($124K) · Disposed of 12,024 shares (Derivative Conversion) · Acquired 4,008 American Depositary Shares (Derivative Conversion) · 1 more |
| 21 Sep 2026 | 144 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statemen... |
| 02 Sep 2026 |
Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER
Received 17,817 shares by exercise or conversion ($6.06K) · Disposed of 17,817 shares (Derivative Conversion) · Acquired 5,939 American Depositary Shares (Derivative Conversion) · 1 more |
| 19 Aug 2026 |
Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER
Received 11,817 shares by exercise or conversion ($4.02K) · Disposed of 11,817 shares (Derivative Conversion) · Acquired 3,939 American Depositary Shares (Derivative Conversion) · 1 more |
| 07 Aug 2026 |
Form 4: Berrios John Joseph, Chief Commercial Officer
Received 140,766 shares as a grant or award · Granted 174,612 Share option (right to buy) |
| 07 Aug 2026 |
Form 3: Berrios John Joseph, Chief Commercial Officer
No securities owned |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 |
Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER
Received 11,817 shares by exercise or conversion ($4.02K) · Disposed of 11,817 shares (Derivative Conversion) · Acquired 3,939 American Depositary Shares (Derivative Conversion) · 1 more |
| 24 Jul 2026 |
Form 4: Fmr Llc, 10% owner
Disposed of 17,452 American Depositary Shares (Open Market Sale) ($874K) |
| 15 Jul 2026 |
Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER
Received 23,634 shares by exercise or conversion ($8.04K) · Disposed of 23,634 shares (Derivative Conversion) · Acquired 7,878 American Depositary Shares (Derivative Conversion) · 1 more |
| 29 Jun 2026 |
Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER
Received 23,634 shares by exercise or conversion ($8.04K) · Disposed of 23,634 shares (Derivative Conversion) · Acquired 7,878 American Depositary Shares (Derivative Conversion) · 1 more |
| 25 Jun 2026 | 144 |
Loading...